In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of Guardant Health Inc (NASDAQ: GH) closed at $40.24 in the last session, down -1.06% from day before closing price of $40.67. In other words, the price has decreased by -$1.06 from its previous closing price. On the day, 1.24 million shares were traded.
Ratios:
We take a closer look at GH’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.76 and its Current Ratio is at 4.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Mizuho on April 10, 2025, initiated with a Outperform rating and assigned the stock a target price of $55.
On January 23, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $60.
Guggenheim Upgraded its Neutral to Buy on June 28, 2024, while the target price for the stock was maintained at $36.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 19 ’25 when Tariq Musa bought 116 shares for $40.04 per share.
Talasaz AmirAli sold 106,784 shares of GH for $5,233,421 on May 01 ’25. The Co-Chief Executive Officer now owns 2,202,672 shares after completing the transaction at $49.01 per share. On May 02 ’25, another insider, Talasaz AmirAli, who serves as the Co-Chief Executive Officer of the company, sold 13,932 shares for $50.47 each. As a result, the insider received 703,151 and left with 2,188,740 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 6.44.
Stock Price History:
Over the past 52 weeks, GH has reached a high of $52.92, while it has fallen to a 52-week low of $20.14. The 50-Day Moving Average of the stock is -7.72%, while the 200-Day Moving Average is calculated to be 15.04%.
Shares Statistics:
A total of 123.65M shares are outstanding, with a floating share count of 117.61M. Insiders hold about 5.07% of the company’s shares, while institutions hold 96.27% stake in the company.
Earnings Estimates
The current rating of Guardant Health Inc (GH) reflects the combined expertise of 14.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.49, with high estimates of -$0.31 and low estimates of -$0.58.
Analysts are recommending an EPS of between -$1.11 and -$2.36 for the fiscal current year, implying an average EPS of -$1.99. EPS for the following year is -$1.69, with 14.0 analysts recommending between -$1.34 and -$2.25.
Revenue Estimates
According to 20 analysts, the current quarter’s revenue is expected to be $211.29M. It ranges from a high estimate of $219.1M to a low estimate of $202.02M. As of the current estimate, Guardant Health Inc’s year-ago sales were $177.24MFor the next quarter, 20 analysts are estimating revenue of $226.36M. There is a high estimate of $228.9M for the next quarter, whereas the lowest estimate is $220.24M.
A total of 23 analysts have provided revenue estimates for GH’s current fiscal year. The highest revenue estimate was $890.4M, while the lowest revenue estimate was $855M, resulting in an average revenue estimate of $884.13M. In the same quarter a year ago, actual revenue was $739.02MBased on 23 analysts’ estimates, the company’s revenue will be $1.07B in the next fiscal year. The high estimate is $1.14B and the low estimate is $1B.
